US Patent No: 7,977,316

Number of patents in Portfolio can not be more than 2000

Prevention and treatment of amyloidogenic diseases

Stats

ALSO PUBLISHED AS: 20080248023
See full text
ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ELAN PHARMACEUTICALS, INC.SOUTH SAN FRANCISCO, CA343

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Schenk, Dale B Pacifica, CA 150 2969

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Eli Lilly and Company (7)
5,441,870 Methods for monitoring cellular processing of .beta.-amyloid precursor protein 117 1992
5,612,486 Transgenic animals harboring APP allele having swedish mutation 133 1993
6,114,133 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreq.41) 83 1994
5,593,846 Methods for the detection of soluble .beta.-amyloid peptide 199 1995
5,605,811 Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein 74 1995
5,837,672 Methods and compositions for the detection of soluble .beta.-amyloid peptide 105 1995
6,284,221 Method for identifying .beta.-amyloid peptide production inhibitors 65 1996
 
BRONSON NUTRITIONALS, LLC (5)
5,869,093 Treatment of immune diseases by oral administration of autoantigens 61 1994
5,645,820 Treatment of autoimmune diseases by aerosol administration of autoantigens 58 1995
5,571,499 Treatment of autoimmune diseases by aerosol administration of autoantigens 70 1995
5,571,500 Treatment of autoimmune diseases through administration by inhalation of autoantigens 59 1995
5,641,474 Prevention of autoimmune diseases by aerosol administration of autoantigens 56 1995
 
AUTOIMMUNE, INC. (4)
5,849,298 Treatment of multiple sclerosis by oral administration of bovine myelin 47 1993
5,869,054 Treatment of multiple sclerosis by oral administration of autoantigens 52 1995
5,733,547 Treatment of autoimmune arthritis by oral administration of type I or type III collagen 50 1995
5,641,473 Treatment of autoimmune diseases by aerosol administration of autoantigens 50 1995
 
MILKHAUS LABORATORY, INC. (3)
5,753,624 Materials and methods for treatment of plaquing disease 80 1996
5,851,996 Materials and methods for treatment of plaquing diseases 85 1998
6,294,171 Methods for treating disease states comprising administration of low levels of antibodies 61 2001
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (3)
5,837,473 Methods of screening for agents affecting the deposition of .beta.-amyloid peptides on amyloid plaques in human tissue 49 1995
5,877,399 Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease 113 1996
6,262,335 Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 52 1998
 
SCIOS NOVA INC. (3)
5,220,013 DNA sequence useful for the detection of Alzheimer's disease 68 1989
5,187,153 Methods of treatment using Alzheimer's amyloid polypeptide derivatives 72 1990
5,387,742 Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease 186 1991
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (3)
4,666,829 Polypeptide marker for Alzheimer's disease and its use for diagnosis 248 1985
5,270,165 Method of diagnosis of amyloidoses 74 1991
5,750,361 Formation and use of prion protein (PRP) complexes 61 1995
 
ANTIGENICS INC. (2)
5,057,540 Saponin adjuvant 159 1990
5,583,112 Saponin-antigen conjugates and the use thereof 85 1992
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (2)
5,750,349 Antibodies to .beta.-amyloids or their derivatives and use thereof 114 1994
5,955,317 Antibodies to .beta.-amyloids or their derivatives and use thereof 77 1997
 
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (2)
5,585,100 Dual carrier immunogenic construct 69 1995
5,955,079 Dual carrier immunogenic construct 56 1995
 
ABBVIE BIOTHERAPEUTICS INC. (1)
5,622,701 Cross-reacting monoclonal antibodies specific for E- and P-selectin 58 1994
 
ALTEON, INC. (1)
5,935,927 Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts 72 1996
 
ALZA CORPORATION (1)
5,972,369 Diffusional implantable delivery system 53 1998
 
AMYLIN PHARMACEUTICALS, INC. (1)
5,266,561 Treatment of type 2 diabetes mellitus 20 1991
 
ANDRULIS PHARMACEUTICALS CORPORATION (1)
5,434,170 Method for treating neurocognitive disorders 83 1993
 
BAYER PHARMACEUTICALS CORPORATION (1)
5,786,180 Monoclonal antibody 369.2B specific for .beta. A4 peptide 65 1995
 
BHI LIMITED PARTNERSHIP (1)
5,643,562 Method for treating amyloidosis 33 1995
 
BOSTON BIOMEDICAL RESEARCH INSTITUTE (1)
2002/0136,718 Immunological control of beta-amyloid levels in vivo 59 2001
 
CEDARS-SINAI MEDICAL CENTER (1)
5,679,348 Immunotherapy for recurrent HSV infections 47 1992
 
CYTRX CORPORATION (1)
5,824,322 Compositions and methods for growth promotion 51 1996
 
DMS PHARMACEUTICAL INC. (1)
5,231,170 Antibodies to dense microspheres 70 1990
 
EPIMMUNE INC. (1)
5,736,142 Alteration of immune response using pan DR-binding peptides 70 1994
 
GLAXOSMITHKLINE BIOLOGICALS S.A. (1)
5,776,468 Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A 70 1996
 
GLAXOSMITHKLINE LLC (1)
5,854,204 A.beta. peptides that modulate .beta.-amyloid aggregation 99 1996
 
HUNTINGTON POTTER (1)
5,780,587 Compounds and methods for inhibiting .beta.-protein filament formation and neurotoxicity 72 1995
 
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (1)
6,150,091 Direct molecular diagnosis of Friedreich ataxia 49 1996
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
4,883,666 Controlled drug delivery system for treatment of neural disorders 188 1987
 
MCW RESEARCH FOUNDATION, INC. (1)
6,057,367 Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses 75 1997
 
NATIONAL RESEARCH COUNCIL OF CANADA (1)
5,773,007 Vaccine compositions 24 1994
 
NEOTOPE BIOSCIENCES LIMITED (1)
6,923,964 Active immunization of AScr for prion disorders 30 2000
 
NEW YORK UNIVERSITY (1)
5,948,763 Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits 17 1996
 
NOVARTIS;CORPORATE INTELLECTUAL PROPERTY (1)
5,866,124 Antiidiotypic antibodies for high molecular weight-melanoma associated antigen 6 1996
 
PARDRIDGE, WILLIAM (1)
5,004,697 Cationized antibodies for delivery through the blood-brain barrier 80 1987
 
PROTEIN DESIGN LABS, INC. (1)
5,530,101 Humanized immunoglobulins 717 1990
 
RAMOT AT TEL-AVIV UNIVERSITY LTD. (1)
5,688,651 Prevention of protein aggregation 86 1994
 
SONORAN DESERT CHEMICALS LIMITED LIABILITY COMPANY (1)
5,290,762 Treatment of inflammation 21 1993
 
SUN HEALTH CORPORATION, INC. (1)
5,192,753 Anti-rheumatoid arthritic drugs in the treatment of dementia 83 1991
 
Syntex (U.S.A.) Inc. (1)
5,208,036 N-(.omega., (.omega.-1)-dialkyloxy)- and N-(.omega., (.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor 120 1990
 
TAURUS INTERNATIONAL MANUFACTURING, INC. (1)
5,972,269 Method of forming cavities in ceramic or metal injection molded parts using a fugitive core 12 1997
 
TEKTRONIX, INC. (1)
5,854,996 Logic signal extraction 27 1994
 
The Research Foundation of State University of New York (1)
5,744,368 Methods for the detection of soluble amyloid .beta.-protein (.beta.AP) or soluble transthyretin (TTR) 59 1993
 
The Scripps Research Institute (1)
5,846,533 Antibodies specific for native PrP.sup.Sc 72 1996
 
TRUSTEES OF BOSTON UNIVERSITY (1)
5,262,303 Ligand/anti-ligand assays for adherent proteins 7 1990
 
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
6,417,178 Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits 70 1997
 
UNIVERSITY OF ROCHESTER (1)
5,231,000 Antibodies to A4 amyloid peptide 103 1991
 
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (1)
2003/0147,882 METHODS FOR AMYLOID REMOVAL USING ANTI-AMYLOID ANTIBODIES 37 1999
 
UNIVERSITY OF WASHINGTON (1)
5,958,883 Animal models of human amyloidoses 73 1995
 
ZOETIS WHC 2 LLC (1)
5,989,566 Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation 49 1996
 
Other [Check patent profile for assignment information] (2)
2002/0009,445 Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease 76 2001
2002/0197,258 Compositions and methods for preventing protein aggregation in neurodegenerative diseases 66 2002

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jan 12, 2015
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 12, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 12, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00